hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06287840 id: 17-301 id: 488294 type: OTHER_GRANT domain: Canadian Institute for Health Research briefTitle: Canadian Bone Strength Development Study acronym: CanBSDS overallStatus: RECRUITING date: 2024-04-01 date: 2028-12-31 date: 2028-12-31 date: 2024-03-01 date: 2024-03-06 name: University of Saskatchewan class: OTHER name: University of Calgary name: The Hospital for Sick Children name: Children's Hospital of Eastern Ontario briefSummary: The goal of this project is to learn about differences in bone development between children with and without type-1 diabetes (T1D). The main questions this study aims to answer are:
3. Assess why T1D may impair sex-specific bone development by exploring the role of disease-related factors (e.g., duration, glucose control, hormones and markers of bone turnover) and fracture history on bone trajectories of children with T1D. It is hypothesized that longer exposure to T1D, poorer glucose control, alterations in hormones, lower bone formation markers and higher history of fracture will be negatively associated with bone trajectories of children with T1D.
Participant's physical growth, bone growth, muscle strength, physical activity and nutrition habits will be assessed and followed up annually for up to 4 years. conditions: Type-1 Diabetes studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 204 type: ESTIMATED measure: Trabecular Thickness (μm) measure: Bone Strength (Failure load) measure: Total, Cortical and Trabecular Bone Area (mm^2) measure: Total, Cortical and Trabecular Bone Density (mg HA/cm^3) measure: Cortical Thickness (μm) measure: Cortical Porosity measure: Trabecular Bone Volume Fraction (%) measure: Trabecular Bone Number (1/mm) measure: Trabecular Bone Separation (μm) measure: Total Body and Hip Bone Mineral Content (g) measure: Total Body and Hip Areal Bone Mineral Density (g/cm^2) measure: Age from Peak Height Velocity (years) measure: Pubertal Development measure: Long Jump (m) measure: Hand Grip (N) measure: Bone Impacts measure: Physical Activity (minutes/day) measure: Food Frequency Questionnaire measure: Health measure: Osteocalcin measure: Procollagen type I N-propeptide (P1NP-N) measure: C-terminal telopepide (CTx) measure: Sclerostin measure: Insulin growth factor-1 measure: Alkaline phosphatase sex: ALL minimumAge: 10 Years maximumAge: 12 Years stdAges: CHILD facility: University of Saskatchewan status: RECRUITING city: Saskatoon state: Saskatchewan zip: S7N5B2 country: Canada name: Saija Kontulainen, PhD role: CONTACT phone: (306)966-1077 email: saija.kontulainen@usask.ca lat: 52.13238 lon: -106.66892 hasResults: False
nctId: NCT06287827 id: 190224 briefTitle: Treatment of Acute Malnutrition in Outpatient Care Services in Venezuela: a Prospective Cohort Research overallStatus: RECRUITING date: 2024-02-14 date: 2024-06-01 date: 2024-06-01 date: 2024-03-01 date: 2024-03-05 name: UNICEF - Venezuela class: OTHER briefSummary: The goal of this observational study is to compare the effectiveness, safety, and efficiency of the simplified protocol, which includes the following three modifications: a) use of a single treatment product (RUTF), b) reduced dose, c) expanded cut-offs, with the standard protocol based on the 2023 World Health Organization (WHO) guidelines for the prevention and treatment of acute malnutrition in children aged 6 to 59 months, in outpatient care services of the states of Bolívar, Capital District, La Guaira, and Miranda of Venezuela.
What is the effectiveness, safety, and efficiency of the simplified protocol, which includes these three modifications (use of a single treatment product (RUTF), reduced dose, expanded cut-offs) when compared to a standard protocol that is based on the 2023 WHO guidelines for the prevention and treatment of acute malnutrition in children aged 6 to 59 months in the outpatient care services of the states of Bolívar, Capital District, La Guaira, and Miranda of Venezuela? This prospective cohort, longitudinal study will be conducted in 4 states, treating children aged 6-59 months diagnosed with uncomplicated AM, defined as WHZ \<-2 or mid-upper-arm circumference (MUAC) \<125mm or bilateral edema. Children will be prospectively followed for 16 weeks or until their recovery.
The effectiveness of the treatment will be measured by the recovery rate, duration of the treatment, and changes in anthropometry (weight, height, and arm circumference). Other treatment effects will also be measured, including how many are admitted to the hospital, death, and relapse rates from the nutritional program. An economic evaluation component will be incorporated. Total costs will be aggregated and presented as costs per child treated and per child recovered. conditions: Acute Malnutrition in Childhood conditions: Wasting conditions: Child Malnutrition studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Simplified protocol name: Standard protocol measure: Recovery rate measure: Weight gain measure: Mid-Upper Arm Circumference (MUAC) gain measure: Duration of the treatment measure: Prevalence of child morbidity measure: Number of RUTF delivered per child measure: Cost per child measure: Prevalence of child stunting sex: ALL minimumAge: 6 Months maximumAge: 59 Months stdAges: CHILD facility: Bolivar State Centers status: RECRUITING city: Puerto Ordaz state: Bolivar zip: 8050 country: Venezuela name: Mary Lares, PhD role: CONTACT phone: +584166203588 email: marylares@hotmail.com name: Mary Lares, PhD role: PRINCIPAL_INVESTIGATOR lat: 8.29829 lon: -62.72198 facility: Ditrict Capital centers status: RECRUITING city: Caracas state: Capital District zip: 1090 country: Venezuela name: Pablo Hernandez, MSc role: CONTACT phone: +584142561345 email: doctuscumliber@gmail.com name: Pablo Hernandez, MSc role: PRINCIPAL_INVESTIGATOR lat: 10.48801 lon: -66.87919 facility: Miranda State Centers status: RECRUITING city: Santa Lucia state: Miranda zip: 1214 country: Venezuela name: Pablo Hernandez, MSc role: CONTACT phone: +584142561345 email: doctuscumliber@gmail.com name: Pablo Hernandez, MSc role: PRINCIPAL_INVESTIGATOR facility: La Guaira State Centers status: RECRUITING city: La Guaira zip: 1160 country: Venezuela name: Claret Mata, MSc role: CONTACT phone: +584142052498 email: clujaym@gmail.com name: Claret Mata, MSc role: PRINCIPAL_INVESTIGATOR lat: 10.59901 lon: -66.9346 hasResults: False
nctId: NCT06287814 id: RECHMPL23_0299 briefTitle: French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-10-31 date: 2028-10-31 date: 2024-03-01 date: 2024-03-01 name: University Hospital, Montpellier class: OTHER briefSummary: Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.
FRENCH-MRD-CRC is the French study of the european GUIDE.MRD project. conditions: Colorectal Cancer conditions: Stage III Colon Cancer conditions: Minimal Residual Disease conditions: Liquid Biopsy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ESTIMATED name: Blood sample/lliquid biopsy measure: 3-year disease-free survival (DFS) measure: Sensitivity (Se) of the ctDNA diagnostics measure: Specificity (Sp) of the ctDNA diagnostics measure: Positive predictive value of the ctDNA diagnostics measure: Negative predictive value of the ctDNA diagnostics measure: Area under the curve of the ctDNA diagnostics measure: Time to clinical recurrence measure: Overall survival measure: Time to molecular recurrence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287801 id: 2024P000271 briefTitle: Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 1 acronym: SPIRE1 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-01-01 date: 2025-06-01 date: 2024-03-01 date: 2024-03-25 name: Massachusetts General Hospital class: OTHER name: Brandeis University name: Patient-Centered Outcomes Research Institute name: Vanderbilt University Medical Center name: Dartmouth-Hitchcock Medical Center name: Indiana University briefSummary: This study consists of three aims focused on examining the feasibility of adding the Geriatric Resources and Assessment for the Care of Elders (GRACE) model to structured Annual Wellness Visits (AWVs) to improve patient and caregiver outcomes and reduce hospitalizations in older adults with complex health needs. The objectives are to:
3. Conduct a pilot clinical trial to assess the feasibility of the AWV GRACE intervention. conditions: Healthy Aging conditions: Health Care Utilization conditions: Health-Related Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Feasibility of a clinical comparative effectiveness trial primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The outcomes assessor team will be blinded to the intervention assignments of participants. Due to the nature of the intervention, the participants, the investigator, and the care providers are unable to be blinded to the participant assignments. whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Annual Wellness Visit name: Geriatric Resources and Assessment for the Care of Elders measure: Hospitalizations measure: Consumer Assessment of Healthcare Providers and Systems Clinician and Group Survey (CG-CAHPS) with Patient Centered Medical Home 1.0 supplement (PCMH CAHPS) measure: Net Promotor Score measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health - Physical Health (PH) and Mental Health (MH) measure: Caregiver Strain measure: Patient's out-of-pocket costs for up to 180 days after enrollment measure: Caregiver's hours spent caregiving. measure: Pilot ACOs Staffing costs measure: Exploratory Geriatric Outcomes - Number of participants with new ICD-10 diagnosis codes measure: Exploratory Geriatric Outcomes- number of participants that complete advanced care planning documents measure: Exploratory Geriatric Outcomes - number of participants with inappropriate medications measure: Covariate - Demographics measure: Covariate - Medicare Entitlement Status measure: Covariate - Elixhauser comorbidity index measure: Covariate - Area Deprivation Index measure: Covariate - Loneliness measure: Exploratory - Hope measure: Covariate - Activities of daily living (ADL) measure: Exploratory - ED visits measure: Exploratory - Observation visits sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287788 id: NFEC-2024-068 briefTitle: A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis overallStatus: RECRUITING date: 2024-03-01 date: 2026-10-30 date: 2026-12-31 date: 2024-03-01 date: 2024-03-01 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: The performance of the predictive models for severe oropharyngeal mucositis established using current oral mucosal contouring method was unsatisfactory in nasopharyngeal carcinoma (NPC). Whereas the predictive model of a mucosal contouring method based on swallowing-induced breakthrough pain exhibited better overall performance. The aim of this prospective, multicenter, observational study was to further explore the predictive efficacy of this mucosal delineation method for radiation-induced oropharyngeal mucositis in NPC. conditions: Radiation-induced Oropharyngeal Mucositis conditions: Swallowing-induced Breakthrough Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 240 type: ESTIMATED measure: The AUC of the predictive model measure: The accuracy, sensitivity, specificity, positive predictive value, negative predictive value and F1 score of the predictive model measure: The important predictors of severe oropharyngeal mucositis in the predictive model sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Jian Guan, Ph.D. role: CONTACT phone: 86+13632102247 email: guanjian5461@163.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06287775 id: NCI-2024-01398 id: NCI-2024-01398 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 10629 type: OTHER domain: JHU Sidney Kimmel Comprehensive Cancer Center LAO id: 10629 type: OTHER domain: CTEP id: UM1CA186691 type: NIH link: https://reporter.nih.gov/quickSearch/UM1CA186691 briefTitle: Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-24 date: 2026-01-31 date: 2026-01-31 date: 2024-03-01 date: 2024-03-12 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer. conditions: Extensive Stage Lung Small Cell Carcinoma conditions: Stage IV Lung Cancer AJCC v8 studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Atezolizumab name: Biopsy name: Biospecimen Collection name: Computed Tomography name: Durvalumab name: Echocardiography name: Iadademstat name: Magnetic Resonance Imaging name: Multigated Acquisition Scan measure: Progression free survival measure: Objective response rate measure: Overall survival measure: Incidence of adverse events measure: Detection of circulating tumor deoxyribonucleic acid (DNA) (ctDNA) minimal residual disease measure: Impact of iadademstat on the correlation of immune checkpoint inhibitors (ICIs) and the presence of cachexia measure: Exposure response relationships of iadademstat in combination with ICIs measure: Changes to small cell lung cancer subtype sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287762 id: 10001737 id: 001737-NR briefTitle: A Natural History Study of RYR1-Related Disorders overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2031-04-30 date: 2031-12-30 date: 2024-03-01 date: 2024-04-26 name: National Institute of Nursing Research (NINR) class: NIH briefSummary: Background:
Eye exam conditions: Ryanodine Receptor 1-Related Myopathy conditions: Ryanodine Receptor 1 Related Disorders studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED measure: Adverse and disease-related events measure: Medical data review measure: Ophthalmology measure: Patient-reported outcomes measure: Pulmonary function measure: Motor function and performance measure: Characterize phenotype and disease course over an extended (2-year) period (total 5 years).Collect exploratory biomarker data. sex: ALL minimumAge: 7 Years maximumAge: 100 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center city: Bethesda state: Maryland zip: 20892 country: United States name: Irene Chrismer role: CONTACT phone: 240-591-8884 email: irene.chrismer@nih.gov name: NIH Clinical Center Office of Patient Recruitment (OPR) role: CONTACT phone: (800) 411-1222 phoneExt: TTY dial 711 email: ccopr@nih.gov lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06287749 id: RECHMPL23_0298 briefTitle: French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2028-10-31 date: 2028-10-31 date: 2024-03-01 date: 2024-03-01 name: University Hospital, Montpellier class: OTHER briefSummary: The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.
FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project conditions: Pancreatic Cancer Resectable conditions: Pancreatic Ductal Adenocarcinoma conditions: Minimal Residual Disease conditions: Liquid Biopsy conditions: ctDNA studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 37 type: ESTIMATED name: Blood sample/Liquid Biopsy measure: 3-year Disease-free survival (DFS) measure: Sensitivity (Se) of the ctDNA diagnostics measure: Specificity (Sp) of the ctDNA diagnostics measure: Positive predictive value of the ctDNA diagnostics measure: Negative predictive value of the ctDNA diagnostics measure: Are Under the Curve of the ctDNA diagnostics measure: Time to clinical recurrence measure: Overall survival measure: Time to molecular recurrence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287736 id: 2023H0386 briefTitle: Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-12-31 date: 2026-12-31 date: 2024-03-01 date: 2024-03-01 name: Ohio State University class: OTHER name: Neuright, Inc. briefSummary: This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers. conditions: Diabetic Peripheral Neuropathy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 60 type: ESTIMATED name: Spinal Cord Stimulator Implantation (SCS) measure: Change in Pain level measure: Change in Diabetic Peripheral Neuropathy (DPN) Pain using the Neuropathic pain diagnostic questionnaire (DN4) measure: Change in PROMIS quality of life in relation to pain level measure: change in neuropathic symptoms using Michigan Neuropathy Screening instrument sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Ohio State University Wexner Medical Center city: Columbus state: Ohio zip: 43210 country: United States name: Uchechi Okafor role: CONTACT phone: 614-366-3439 email: Uchechi.Okafor@osumc.edu name: Brian Dalm, MD role: PRINCIPAL_INVESTIGATOR name: Kristy Townsend, PhD role: SUB_INVESTIGATOR name: Magdalena Blaszkiewicz, PhD role: SUB_INVESTIGATOR name: Miriam Freimer, MD role: SUB_INVESTIGATOR name: Bakri Elsheikh, MD role: SUB_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06287723 id: RECHMPL23_0297 briefTitle: French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM) overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-10-31 date: 2028-10-31 date: 2024-03-01 date: 2024-03-01 name: University Hospital, Montpellier class: OTHER briefSummary: Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.
FRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project. conditions: Colorectal Cancer conditions: Liver Metastases conditions: Stage IV Colorectal Cancer conditions: Minimal Residual Disease conditions: Liquid Biopsy conditions: ctDNA studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Blood sample/Liquid biopsy measure: 3-year disease free survival measure: Sensitivity (Se) of the ctDNA diagnostics measure: Specificity (Sp) of the ctDNA diagnostics measure: Positive predictive value of the ctDNA diagnostics measure: Negative predictive value of the ctDNA diagnostics measure: Area under the curve of the ctDNA diagnostics measure: Time to clinical recurrence measure: Overall survival measure: Time to molecular recurrence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287710 id: CHUBX 2023/32 briefTitle: Fluid Responsiveness Evaluation by a Non-invasive Method in Children, Extended to PREterm Infants - FRENCH-PREMA acronym: FRENCH-PREMA overallStatus: RECRUITING date: 2024-01-17 date: 2024-11-17 date: 2025-04-17 date: 2024-03-01 date: 2024-03-01 name: University Hospital, Bordeaux class: OTHER briefSummary: In this study, the investigators aim to validate a non-invasive marker of fluid-responsiveness in preterm infants (term below 37 gestational week) with acute circulatory failure based on standardized abdominal compression. This would allow physicians to identify which patient could benefit from a fluid expansion, thus avoiding a potentially useless or even dangerous fluid expansion, leading to fluid overload. To this end, the investigators will evaluate the diagnostic accuracy (sensitivity and specificity) of stroke volume variation induced by standardized abdominal compression for the diagnosis of fluid responsiveness (based on the gold-standard test: significant increase in cardiac index after fluid expansion). conditions: Premature Baby 26 to 32 Weeks conditions: Premature Baby 33 to 36 Weeks studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment). measure: Diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of the index test (ΔSVi-AC) for the diagnosis of fluid responsiveness, measure: Diagnostic accuracy of the SAV mean and the ΔPeak for the diagnosis of fluid responsiveness sex: ALL minimumAge: 1 Minute maximumAge: 5 Months stdAges: CHILD facility: Bordeaux Hospital University status: RECRUITING city: Bordeaux zip: 33076 country: France name: Sophie CRAMAREGEAS, MD role: CONTACT phone: 0557821269 name: sophie.cramaregeas@chu-bordeaux.fr role: CONTACT lat: 44.84044 lon: -0.5805 hasResults: False